Zevra Therapeutics (NASDAQ:ZVRA) Issues Earnings Results

Zevra Therapeutics (NASDAQ:ZVRA) announced its quarterly earnings results on Wednesday. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.14, FiscalAI reports. The company had revenue of $39.66 million for the quarter, compared to the consensus estimate of $33.88 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%.

Here are the key takeaways from Zevra Therapeutics’ conference call:

• Second-quarter revenue rose 53% year over year to $39.7 million, driven by $30.2 million in U.S. MIPLYFFA sales, which increased 23% sequentially and 40% year over year.
• MIPLYFFA enrollment reached 184 prescription forms through June 30, including 23 in the first half of 2026, with a diverse mix of newly and previously diagnosed patients, children and adults, and specialty-center and community-practice prescribers.
• Zevra requested an EMA re-examination of arimoclomol’s negative CHMP opinion and expects a decision in the fourth quarter; management cited long-term, pediatric, expanded-access, and safety data as support, but approval remains uncertain.
• Celiprolol’s Phase III DISCOVER trial remains early and event-driven, with 66 of 150 patients enrolled and only three confirmed events versus the 28 needed for interim analysis, prompting efforts to accelerate enrollment and regulatory discussions.
• Cash, cash equivalents, and investments totaled $260.2 million at quarter-end, up approximately $23.4 million sequentially, giving Zevra flexibility to fund MIPLYFFA expansion, celiprolol, and potential external opportunities without relying on capital markets.

Zevra Therapeutics Trading Up 0.1%

ZVRA traded up $0.01 during midday trading on Wednesday, hitting $10.53. The company’s stock had a trading volume of 776,877 shares, compared to its average volume of 1,361,412. Zevra Therapeutics has a 52-week low of $7.16 and a 52-week high of $15.03. The firm has a 50-day moving average price of $12.32 and a two-hundred day moving average price of $10.54. The firm has a market cap of $622.53 million, a P/E ratio of 5.29 and a beta of 0.91.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP purchased a new position in Zevra Therapeutics during the third quarter worth approximately $8,676,000. Rubric Capital Management LP increased its position in Zevra Therapeutics by 60.8% during the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock worth $17,253,000 after purchasing an additional 740,584 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in shares of Zevra Therapeutics by 15.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after purchasing an additional 550,000 shares in the last quarter. Nantahala Capital Management LLC raised its stake in shares of Zevra Therapeutics by 34.0% during the third quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock valued at $18,753,000 after purchasing an additional 500,000 shares during the period. Finally, Algert Global LLC acquired a new position in Zevra Therapeutics in the 3rd quarter worth $3,980,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ZVRA shares. Cantor Fitzgerald raised their price target on Zevra Therapeutics from $24.00 to $34.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. UBS Group reaffirmed a “buy” rating on shares of Zevra Therapeutics in a research note on Wednesday, June 24th. Maxim Group boosted their target price on shares of Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. BTIG Research reduced their target price on shares of Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a report on Monday, July 27th. Finally, Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Nine equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Zevra Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $26.86.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.